For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $0.99 in the prior trading day, Century Therapeutics Inc (NASDAQ: IPSC) closed at $0.99, up 0.01%. In other words, the price has increased by $0.01 from its previous closing price. On the day, 1.94 million shares were traded. IPSC stock price reached its highest trading level at $1.05 during the session, while it also had its lowest trading level at $0.9064.
Ratios:
Our goal is to gain a better understanding of IPSC by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.25 and its Current Ratio is at 6.25. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.23.
Upgrades & Downgrades
In the most recent recommendation for this company, Rodman & Renshaw on August 08, 2024, initiated with a Buy rating and assigned the stock a target price of $6.
On August 28, 2023, JP Morgan Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $28 to $5.
On December 27, 2022, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $19.Chardan Capital Markets initiated its Buy rating on December 27, 2022, with a $19 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 22 ’25 when Cowan Chad bought 58,060 shares for $0.85 per share. The transaction valued at 49,252 led to the insider holds 1,045,087 shares of the business.
Pfeiffenberger Brent bought 52,000 shares of IPSC for $30,352 on Dec 12 ’25. The President and CEO now owns 3,322,990 shares after completing the transaction at $0.58 per share. On Dec 08 ’25, another insider, Carr Douglas, who serves as the SVP Finance & Operations of the company, sold 257 shares for $0.53 each. As a result, the insider received 137 and left with 404,874 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IPSC now has a Market Capitalization of 86959544 and an Enterprise Value of -930175. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.77 while its Price-to-Book (P/B) ratio in mrq is 0.49. Its current Enterprise Value per Revenue stands at -0.008 whereas that against EBITDA is 0.095.
Stock Price History:
The Beta on a monthly basis for IPSC is 1.73, which has changed by -0.05238098 over the last 52 weeks, in comparison to a change of 0.14778805 over the same period for the S&P500. Over the past 52 weeks, IPSC has reached a high of $1.18, while it has fallen to a 52-week low of $0.34. The 50-Day Moving Average of the stock is 56.71%, while the 200-Day Moving Average is calculated to be 76.54%.
Shares Statistics:
The stock has traded on average 1.27M shares per day over the past 3-months and 1956110 shares per day over the last 10 days, according to various share statistics. A total of 86.53M shares are outstanding, with a floating share count of 45.80M. Insiders hold about 47.60% of the company’s shares, while institutions hold 22.77% stake in the company. Shares short for IPSC as of 1765756800 were 246333 with a Short Ratio of 0.19, compared to 1763078400 on 497543. Therefore, it implies a Short% of Shares Outstanding of 246333 and a Short% of Float of 0.4.
Earnings Estimates
The dynamic stock of Century Therapeutics Inc (IPSC) is currently attracting attention from 1.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.3, with high estimates of -$0.2 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$0.13 and -$0.27 for the fiscal current year, implying an average EPS of -$0.2. EPS for the following year is -$1.23, with 2.0 analysts recommending between -$0.9 and -$1.56.
Revenue Estimates
A total of 3 analysts have provided revenue estimates for IPSC’s current fiscal year. The highest revenue estimate was $109.16M, while the lowest revenue estimate was $109.16M, resulting in an average revenue estimate of $109.16M. In the same quarter a year ago, actual revenue was $6.59M
